Back to results
US 9,068,231 B2Granted
Method for screening cancer therapeutic agent using galectin-3, GSK-3β, and fascin-1
AssigneeNational Cancer Center
InventorsKyung-Hee Chun, Seok-Jun Kim, Teak-Chin Cheong, Il-Ju Choi, Yeon Su Lee, Sang-Jin Lee
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3β.
Claims5
An in vitro method for screening a compound capable of inhibiting the binding of GSK-3β with galectin-3 and down-regulating the expression of fascin-1 in gastric cancer cells, comprising:
- a) treating gastric cancer cells with a candidate agent;
- b) measuring (i) binding of galectin-3 with glycogen synthetase kinase-3β (GSK-3β) in the nucleus of the gastric cancer cell treated with the candidate agent, and (ii) expression level of fascin-1 in the gastric cancer cells treated with the candidate agent;
- and
- c) identifying a candidate agent as the compound when the binding of galectin-3 and GSK-3β in the nucleus measured in step b)(i), and the expression level of fascin-1 measured in step b)(ii) are reduced in the gastric cancer cells as compared to the gastric cancer cells before treatment with the candidate agent,
- wherein the candidate agent is a galectin-3 siRNA.
2 more elements
Dependencies are inferred from the claim text.